Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,007 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 155 · Balance 31,007 F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $772.76 · Expires 2036-01-02 | Direct | 1,962 |
Reported balance
After 2026-01-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-02 · Grant · Acquired 1,962 · Balance 1,962 F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | Indirectby Spouse | 750 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 750 |
| Common StockSEC Table I · non-derivative | Indirectby Spouse/Cust Son | 400 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 400 |
| Common StockSEC Table I · non-derivative | Indirectby Trust for Son | 1,000 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2020 Filed May 14, 2020 01:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $575.00 | $172,500.00 |
DisclosureSEC source: 0001708138-20-000057 · edgardoc.xml · nonDerivative · entry 4 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse/Cust Son Disclosed balance after: 3,400 Read SEC document |
| May 11, 2020 Filed May 14, 2020 01:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 250 | $575.00 | $143,750.00 |
DisclosureSEC source: 0001708138-20-000057 · edgardoc.xml · nonDerivative · entry 3 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse Disclosed balance after: 2,150 Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $33.42 | $0.00 |
DisclosureSEC source: 0001237899-20-000013 · edgardoc.xml · derivative · entry 9 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 2,500 shares Expires 2021-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $455.00 | $227,500.00 |
DisclosureSEC source: 0001237899-20-000013 · edgardoc.xml · nonDerivative · entry 8 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust for Son Disclosed balance after: 9,000 Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $450.00 | $225,000.00 |
DisclosureSEC source: 0001237899-20-000013 · edgardoc.xml · nonDerivative · entry 7 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust for Son Disclosed balance after: 9,500 Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 400 | $457.00 | $182,800.00 |
DisclosureSEC source: 0001237899-20-000013 · edgardoc.xml · nonDerivative · entry 6 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse/Cust Son Disclosed balance after: 3,700 Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 400 | $450.00 | $180,000.00 |
DisclosureSEC source: 0001237899-20-000013 · edgardoc.xml · nonDerivative · entry 5 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse/Cust Son Disclosed balance after: 4,100 Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $455.00 | $136,500.00 |
DisclosureSEC source: 0001237899-20-000013 · edgardoc.xml · nonDerivative · entry 4 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse Disclosed balance after: 2,400 Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $450.00 | $135,000.00 |
DisclosureSEC source: 0001237899-20-000013 · edgardoc.xml · nonDerivative · entry 3 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse Disclosed balance after: 2,700 Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,500 | $460.00 | $1,150,000.00 |
DisclosureSEC source: 0001237899-20-000013 · edgardoc.xml · nonDerivative · entry 2 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,415 Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,500 | $33.42 | $83,550.00 |
DisclosureSEC source: 0001237899-20-000013 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,361 | $0.00 Strike: $374.12 | $0.00 |
DisclosureSEC source: 0001237899-20-000001 · edgardoc.xml · derivative · entry 8 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,361 Underlying: Common Stock · 4,361 shares Expires 2030-01-02 F5 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $24.41 | $0.00 |
DisclosureSEC source: 0001237899-20-000001 · edgardoc.xml · derivative · entry 7 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2020-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 320 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-20-000001 · edgardoc.xml · nonDerivative · entry 3 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,415 F3 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 15,000 | $371.98 | $5,579,700.00 |
DisclosureSEC source: 0001237899-20-000001 · edgardoc.xml · nonDerivative · entry 2 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,095 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 15,000 shares of the Issuer's common stock on January 2, 2020 at prices ranging from $371.98 to $371.99. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2020. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 15,000 | $24.41 | $366,150.00 |
DisclosureSEC source: 0001237899-20-000001 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,784 | $0.00 Strike: $371.40 | $0.00 |
DisclosureSEC source: 0001237899-19-000004 · edgardoc.xml · derivative · entry 5 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,784 Underlying: Common Stock · 3,784 shares Expires 2029-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 323 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000004 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,095 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 10, 2018 Filed May 11, 2018 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,000 | $288.00 | $1,152,000.00 |
DisclosureSEC source: 0001708138-18-000006 · edgardoc.xml · nonDerivative · entry 5 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,772 Read SEC document |
| May 10, 2018 Filed May 11, 2018 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,000 | $287.00 | $861,000.00 |
DisclosureSEC source: 0001708138-18-000006 · edgardoc.xml · nonDerivative · entry 4 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,772 Read SEC document |
| May 10, 2018 Filed May 11, 2018 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,000 | $286.00 | $858,000.00 |
DisclosureSEC source: 0001708138-18-000006 · edgardoc.xml · nonDerivative · entry 3 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,772 Read SEC document |
| May 10, 2018 Filed May 11, 2018 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,000 | $285.00 | $855,000.00 |
DisclosureSEC source: 0001708138-18-000006 · edgardoc.xml · nonDerivative · entry 2 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,772 Read SEC document |
| May 09, 2018 Filed May 11, 2018 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7,000 | $285.29 | $1,997,030.00 |
DisclosureSEC source: 0001708138-18-000006 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,772 F1 · price: Represents volume-weighted average price of sales of 7,000 shares of Company stock on May 9, 2018 at prices ranging from $285.00 to $285.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 9, 2018 at each separate price. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,439 | $0.00 Strike: $380.95 | $0.00 |
DisclosureSEC source: 0001708138-18-000002 · edgardoc.xml · derivative · entry 6 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,439 Underlying: Common Stock · 7,439 shares Expires 2028-01-02 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $23.84 | $0.00 |
DisclosureSEC source: 0001708138-18-000002 · edgardoc.xml · derivative · entry 5 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 15,000 | $23.84 | $357,600.00 |
DisclosureSEC source: 0001708138-18-000002 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,772 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,830 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001237899-17-000002 · edgardoc.xml · derivative · entry 6 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,830 Underlying: Common Stock · 7,830 shares Expires 2027-01-03 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $19.69 | $0.00 |
DisclosureSEC source: 0001237899-17-000002 · edgardoc.xml · derivative · entry 5 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2017-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 7,000 | $19.69 | $137,830.00 |
DisclosureSEC source: 0001237899-17-000002 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,772 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.